PI Industries has announced its unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors considered and approved these results, which include a statement of assets and liabilities and cash flow statements. The limited review report by the Statutory Auditors has also been provided. The results cover performance across the company’s segments, detailing revenue, profit, and other comprehensive income.
PI Industries Announces Financial Results for Q2 FY27
PI Industries has officially released its unaudited financial results for the quarter and half-year ended September 30, 2026. The announcement confirms the Board of Directors’ approval of both standalone and consolidated financial statements. These results provide a detailed overview of the company’s performance during the specified periods, reflecting its financial standing and operational outcomes.
Key Financial Highlights
The reported figures indicate the company’s financial trajectory, with standalone revenue from operations reaching ₹15,335 million for the quarter ended September 30, 2026, and ₹31,324 million for the half-year. Profit after tax for the standalone entity stood at ₹2,071 million for the quarter and ₹5,486 million for the half-year. Consolidated revenue from operations for the same periods were ₹17,018 million and ₹34,041 million respectively, with a consolidated profit after tax of ₹1,222 million for the quarter and ₹3,664 million for the half-year.
Segment Performance Overview
The company’s performance is further detailed through its segment reporting. The Agro chemicals segment contributed significantly to the consolidated revenue, with figures for the quarter and half-year ending September 30, 2026, standing at ₹16,280 million and ₹32,768 million respectively. The Pharma segment reported consolidated revenues of ₹759 million and ₹1,301 million for the respective periods. Segment results show a profit before tax of ₹2,473 million for the Agro chemicals segment and a loss of ₹601 million for the Pharma segment in the quarter.
Balance Sheet and Cash Flow Statements
The accompanying financial statements also provide a snapshot of PI Industries’ assets and liabilities as of September 30, 2026. Total assets for the standalone entity were ₹136,557 million, with total equity and liabilities at the same figure. On a consolidated basis, total assets amounted to ₹138,658 million. The cash flow statements detail the net cash inflow from operating activities, investing activities, and financing activities for the half-year periods, highlighting the company’s liquidity and cash management strategies.
Notes and Auditor Review
The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 4, 2026. The statements have been prepared in accordance with Indian Accounting Standards (Ind AS). The review report from Price Waterhouse Chartered Accountants LLP confirms that, based on their review, nothing has come to their attention that would indicate the statement is not free of material misstatement.
Source: BSE
